Collegium Pharmaceutical Stock News

-- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and.

In a report issued on March 4, Serge Belanger from Needham maintained a Hold rating on Amag Pharmaceuticals (AMAG). The company's shares closed last

In a report issued on March 4, Serge Belanger from Needham maintained a Hold rating on Amag Pharmaceuticals ( AMAG – Research Report ). The company’s shares closed last Monday at $7.68, close to i

Needham analyst Serge Belanger maintained a Hold rating on BioCryst (BCRX) on March 5. The company's shares closed last Monday at $4.11. According to

Needham analyst Serge Belanger maintained a Hold rating on BioCryst ( BCRX – Research Report ) on March 5. The company’s shares closed last Monday at $4.11. According to TipRanks.com , Belanger is

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cantel Medical

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Investment analysts at G.Research lowered their FY2020 earnings estimates for Collegium Pharmaceutical in a research note issued on Tuesday, March 3rd. G

Mackay Shields LLC acquired a new position in Collegium Pharmaceutical Inc (NASDAQ:COLL) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fu

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals (EYPT) and Aurinia

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals ( EYPT – Research Report ) and Aurinia Pharmaceuticals ( AUPH – Research R

Bank of Montreal Can lifted its position in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 248.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 252,22

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Research analysts at G.Research upped their FY2023 earnings per share (EPS) estimates for Collegium Pharmaceutical in a note issued to investors on Tuesd

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT), with a price target of $18.00. The

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $18.00 . The company’s shares closed la

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (ATRS) and Durect (DRRX) with bullish